Cargando…
EE197 Efficacy and Economic Impact of Metformin Plus Glibenclamide Treatment During the COVID-19 Pandemic in Ecuadorian Outpatients With Type II Diabetes Mellitus
Autores principales: | Zambrano, R, Cabezas, M, Loor, G, Aguirre, N, Miño, C |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9747433/ http://dx.doi.org/10.1016/j.jval.2022.09.447 |
Ejemplares similares
-
Prevalence and risk factors of depression, anxiety, and stress in an Ecuadorian outpatient population with type II diabetes mellitus: A cross-sectional study (STROBE)
por: Cárdenas, Luisa, et al.
Publicado: (2022) -
Cost-Effectiveness of Saxagliptin Compared With Glibenclamide as a Second-Line Therapy Added to Metformin for Type 2 Diabetes Mellitus in Ethiopia
por: Bekele, Mengistu, et al.
Publicado: (2021) -
Genotoxicity Studies Performed in the Ecuadorian Population
por: Paz-y-Miño, César, et al.
Publicado: (2012) -
Glibenclamide or Metformin Combined with Honey Improves Glycemic Control in Streptozotocin-Induced Diabetic Rats
por: Erejuwa, Omotayo Owomofoyon, et al.
Publicado: (2011) -
Glibenclamide, metformin, and insulin for the treatment of gestational diabetes: a systematic review and meta-analysis
por: Balsells, Montserrat, et al.
Publicado: (2015)